The Longer, the Better: Continuous Glucose Monitoring Use for ≥90% Is Superior to 70%–89% in Achieving Tighter Glycemic Outcomes in Children with Type 1 Diabetes
Authors:
- 2 April 2025
- journal article
- research article
- Published by SAGE Publications in Diabetes Technology & Therapeutics
- Vol. 27 (4) , 301-307
Abstract
Objective: The recommended threshold for the time spent on continuous glucose monitoring (CGM) is established at 70%. However, glucose outcomes in children with type 1 diabetes (CwD) using CGM for a different proportion of time within this threshold have not been evaluated yet. The study aims to compare glycemic parameters among CwD who spent 70%–89% and ≥90% on CGM using the population-wide data from the Czech national pediatric diabetes registry ČENDA. Methods: CwD aged 70% of the time and did not change the type of therapy throughout the year 2023 were included and divided into two groups based on the time they spent on CGM—70%–89% versus ≥90%. HbA1c, times in standard glycemic ranges, mean glucose, and coefficient of variability (CV) were compared between the groups and by treatment modalities. Results: Data from 1977 CwD (1035 males and 942 females) were evaluated. Among them, 404 participants (20.4%) used CGM 70%–89% of the time, and 1573 participants (79.6%) ≥90% of the time. Compared with the 70–89% group, the ≥90% CGM users achieved significantly lower HbA1c levels (51 mmol/mol, 6.8% vs. 58 mmol/mol, 7.4%, P < 0.001), higher time in range (72% vs. 60%, P < 0.001), and lower mean glucose and CV (8.1 mmol/L, 146 mg/dL vs. 9.1 mmol/L, 164 mg/dL and 37% vs. 40%, respectively, both P < 0.001). Analogous results were seen irrespective of the treatment modality. The differences persisted after propensity score adjustment. Conclusion: CGM use for ≥90% is associated with tighter glycemic control compared with 70%–89% use. Therefore, it is essential to motivate CwD to use CGM for the longest possible time and search for suitable options to overcome barriers in uninterrupted CGM monitoring.Keywords
This publication has 21 references indexed in Scilit:
- Introduction of continuous glucose monitoring (CGM) is a key factor in decreasing HbA1c in war refugee children with type 1 diabetesDiabetes Research and Clinical Practice, 2024
- Prevalence and Description of the Skin Reactions Associated with Adhesives in Diabetes Technology Devices in an Adult Population: Results of the CUTADIAB StudyDiabetes Technology & Therapeutics, 2023
- Accuracy of the Third Generation of a 14-Day Continuous Glucose Monitoring SystemDiabetes Therapy, 2023
- Accuracy and Safety of Dexcom G7 Continuous Glucose Monitoring in Adults with DiabetesDiabetes Technology & Therapeutics, 2022
- Glycemic Improvement Using Continuous Glucose Monitoring by Baseline Time in Range: Subgroup Analyses from the DIAMOND Type 1 Diabetes StudyDiabetes Technology & Therapeutics, 2021
- Persistent heterogeneity in diabetes technology reimbursement for children with type 1 diabetes: The SWEET perspectivePediatric Diabetes, 2019
- Continuous Glucose Monitoring vs Conventional Therapy for Glycemic Control in Adults With Type 1 Diabetes Treated With Multiple Daily Insulin InjectionsJAMA, 2017
- Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trialThe Lancet, 2016
- Continuous glucose monitoring for patients with type 1 diabetes and impaired awareness of hypoglycaemia (IN CONTROL): a randomised, open-label, crossover trialThe Lancet Diabetes & Endocrinology, 2016
- Comparison of Different Treatment Modalities for Type 1 Diabetes, Including Sensor-Augmented Insulin Regimens, in 52 Weeks of Follow-Up: A COMISAIR StudyDiabetes Technology & Therapeutics, 2016